Loading…
Cytek Biosciences, Inc. is projected to rise to $4.17 by 2027, a +5% move from its current price of $3.99. CTKB is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $3.85 | $3.99 | $4.13 | +0.01% |
| May 30 | $3.80 | $3.99 | $4.19 | +0.03% |
| May 31 | $3.76 | $3.99 | $4.24 | +0.04% |
| Jun 1 | $3.72 | $3.99 | $4.28 | +0.06% |
| Jun 2 | $3.69 | $3.99 | $4.32 | +0.07% |
| Jun 3 | $3.66 | $3.99 | $4.35 | +0.09% |
| Jun 4 | $3.64 | $3.99 | $4.38 | +0.10% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $3.64 | $3.99 | $4.38 | +0.10% |
| Week 2 | $3.51 | $4.00 | $4.56 | +0.20% |
| Week 3 | $3.41 | $4.00 | $4.70 | +0.30% |
| Week 4 | $3.33 | $4.01 | $4.83 | +0.40% |
| Week 5 | $3.26 | $4.01 | $4.94 | +0.50% |
| Week 6 | $3.20 | $4.01 | $5.04 | +0.60% |
| Week 7 | $3.14 | $4.02 | $5.14 | +0.70% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Cytek Biosciences, Inc. is a healthcare company that provides cell analysis solutions to support biomedical research and clinical applications. Its product portfolio includes Cytek aurora and northern lights systems, Cytek aurora evo systems, the Cytek Aurora CS System for additional downstream genomic and proteomic studies, enhanced small particle detection, Amnis imagestream imaging flow cytometers, Guava Muse cell analyzers, Muse micro cell analyzers, Guava easyCyte flow cytometers, and Orion reagent cocktail preparation systems.
It also offers reagents and kits such as cFlu reagents, automated micro-sampling and automated sample loader systems, and SpectroFlo software to support workflow and data analysis.
Cytek was founded in 1992 and is headquartered in Fremont, California. The company serves pharmaceutical and biopharma companies, academic research centers, and contract research organizations, distributing products through direct channels in North America, Europe, China, and the Asia-Pacific region, with additional distributors in Europe, Latin America, and the Middle East.
Cytek Biosciences, Inc. (CTKB) is a healthcare stock currently priced at $4.01 per share. It has a market capitalization of $517.86M and ranks 3018 by market cap. The near-term setup suggests a mixed path in the forecast with a neutral entry in 2026 and stronger upside in later years, as reflected by the forecasted average price rising to multi-year highs in the 2030s and beyond.
Forecasts indicate a broad upside over the long horizon, with the 2026 average at $4.01 and a 0 return, and substantial gains anticipated toward 2030 and past. The data imply meaningful upside in later years, culminating in markedly higher averages by 2050, signaling a potential multi-bagger scenario from the current price.
A major floor 37.1% below — a decisive break under it would weaken the trend.
The nearest floor, 15.9% below — buyers have tended to step in here.
The nearest ceiling, 23.8% above — a clean break opens room to run.
A major ceiling 42.4% above — clearing it would confirm fresh momentum.
Key CTKB support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of CTKB market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $3.94 | Buy | $3.92 | Buy |
| MA 10 | $3.73 | Buy | $3.92 | Buy |
| MA 20 | $4.15 | Sell | $4.06 | Sell |
| MA 50 | $4.37 | Sell | $4.28 | Sell |
| MA 100 | $4.58 | Sell | $4.42 | Sell |
| MA 200 | $4.48 | Sell | $4.47 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 45.68 | Neutral |
| Stoch RSI (14) | 53.78 | Neutral |
| CCI (20) | -24.14 | Neutral |
| Williams %R (14) | -59.42 | Info |
| MACD (12,26,9) | 0.01 | Buy |
| ROC (12) | -13.45 | Sell |
| Bollinger %B (20,2) | 0.42 | Neutral |
| Stochastic %K (14) | 40.58 | Neutral |
| TRIX (15) | -0.60 | Sell |
| Awesome (5,34) | -0.38 | Sell |
| Ultimate (7,14,28) | 68.05 | Neutral |
| Momentum (10) | -0.05 | Sell |
| Aroon Osc (25) | -24.00 | Sell |
| Hull MA (9) | 4.11 | Sell |
| ADX (14) | 19.40 | Neutral |
| ATR (14) | 0.13 | Info |
The 30-day technical picture shows a bearish to neutral tilt in the near term. RSI14 is 50, and the stock sits between moving averages with a SMA50 of $4.38 and a SMA200 of $4.48, suggesting that near-term momentum is flat to soft.
Key support is at $3.36 and resistance at $4.94, indicating a defined trading range near the current level. The 30-day price range spans from $3.14 to $5.13, highlighting the potential for swing movement within that band over the next month.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $3.36 | $3.99 | $5.10 | 0% | Neutral | |
| $3.22 | $4.17 | $5.79 | +5% | Neutral | |
| $3.44 | $4.62 | $6.70 | +16% | Neutral | |
| $4.31 | $5.98 | $8.96 | +50% | Bullish | |
| $4.22 | $6.01 | $9.28 | +51% | Bullish | |
| $3.97 | $5.80 | $9.19 | +45% | Bullish | |
| $4.30 | $6.43 | $10.42 | +61% | Bullish | |
| $3.97 | $6.08 | $10.05 | +52% | Bullish | |
| $4.11 | $6.42 | $10.82 | +61% | Bullish | |
| $5.15 | $8.22 | $14.09 | +106% | Bullish | |
| $5.49 | $9.63 | $17.76 | +141% | Bullish | |
| $9.65 | $20.05 | $41.07 | +402% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $3.36 | $3.99 | $4.73 | +0.00% |
| June 2026 | $3.48 | $4.12 | $5.00 | +3.22% |
| July 2026 | $3.38 | $4.04 | $4.99 | -1.84% |
| August 2026 | $3.42 | $4.12 | $5.15 | +1.83% |
| September 2026 | $3.49 | $4.23 | $5.35 | +2.77% |
| October 2026 | $3.34 | $4.08 | $5.21 | -3.63% |
| November 2026 | $3.17 | $3.89 | $5.01 | -4.60% |
| December 2026 | $3.18 | $3.93 | $5.10 | +1.09% |
Click any year to see its month-by-month CTKB forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Cytek Biosciences, Inc.'s 2026 outlook centres on $3.99, within a $3.36 to $5.10 range. That marks a 0% change versus current levels. A consolidation phase looks the most probable path here.
By 2027, CTKB could reach as high as $5.79, with a base case around $4.17 and support toward $3.22 — roughly +5% from $3.99. Price action looks broadly range-bound.
Expect CTKB to range from $3.44 to $6.70 through 2028. The $4.62 average target implies a +16% move from current prices. That is up +11% on the projected 2027 average. A consolidation phase looks the most probable path here.
The CTKB price prediction for 2029 points to an average of $5.98 (low $4.31, high $8.96) — a potential gain of +50% on today's $3.99. Momentum favours further upside here.
In 2030, CTKB is projected to trade between $4.22 and $9.28, averaging $6.01 — a potential gain of +51% from today's $3.99. That is up +1% on the projected 2029 average. Buyers look set to stay in control over this stretch.
Cytek Biosciences, Inc.'s 2031 outlook centres on $5.80, within a $3.97 to $9.19 range. That is -3% versus the projected 2030 average. That marks a +45% change versus current levels. Momentum favours further upside here.
By 2032, CTKB could reach as high as $10.42, with a base case around $6.43 and support toward $4.30 — roughly +61% from $3.99. Buyers look set to stay in control over this stretch.
Expect CTKB to range from $3.97 to $10.05 through 2033. The $6.08 average target implies a +52% move from current prices. That is -6% versus the projected 2032 average. Momentum favours further upside here.
The CTKB price prediction for 2034 points to an average of $6.42 (low $4.11, high $10.82) — a potential gain of +61% on today's $3.99. Buyers look set to stay in control over this stretch.
In 2035, CTKB is projected to trade between $5.15 and $14.09, averaging $8.22 — a potential gain of +106% from today's $3.99. That is up +28% on the projected 2034 average. Momentum favours further upside here.
Cytek Biosciences, Inc.'s 2040 outlook centres on $9.63, within a $5.49 to $17.76 range. That is up +17% on the projected 2035 average. That marks a +141% change versus current levels. Buyers look set to stay in control over this stretch.
By 2050, CTKB could reach as high as $41.07, with a base case around $20.05 and support toward $9.65 — roughly +402% from $3.99. Momentum favours further upside here.
Investing $1,000 in CTKB today (≈ 250.626566 CTKB) could be worth
$5,024.91
+$4,024.91 (+402%) by 2050 · US Dollar
Based on the average projected CTKB price of $20.05 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in CTKBwould be worth at today's price.
$1,000 invested in CTKB on May 27, 2025 (≈ 389.105068 CTKB) would be worth
$1,552.53
+$552.53 (+55.3%) today · 1.55× · US Dollar
Based on a CTKB entry price of $2.57 vs. today's $3.99.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $3.77 | $1,058.36 | +5.8% |
| 1 month ago | $4.46 | $894.62 | -10.5% |
| 3 months ago | $4.4 | $906.82 | -9.3% |
| 6 months ago | $5.65 | $706.19 | -29.4% |
| 1 year ago | $2.57 | $1,552.53 | +55.3% |
| All time (4.8y) ago | $18.76 | $212.69 | -78.7% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our CTKB forecast.
Our base-case forecast reaches $8.00 around 2035.
Implied market cap at $8.00: $1.03B
The multi-year forecast shows a bullish trajectory beginning in the late 2020s and continuing into the 2030s and beyond. In 2029 the avg is $6.07 with a 51.4 ROI, and in 2030 the avg is $6.03 with a 50.3 ROI, both at bullish sentiment levels. By 2031 the avg falls to $5.81 and 2032 rises to $6.50 with corresponding bullish readings, indicating upside potential with volatility across the decade.
By 2035 the forecast calls for an avg of $8.35 with an 108.3 ROI, and by 2040 an avg of $9.62 with a 139.9 ROI. The path continues to 2050 with an avg of $20.15 and a 402.5 ROI, all characterized by bullish sentiment. These figures point to meaningful long-run upside relative to the current price, tempered by year-to-year variability and the inherent uncertainty of markets.
Tap a question to reveal the answer.
2030: min $4.17, avg $6.03, max $9.45 with ROI 50.3 and sentiment BULLISH.
The forecast shows bullish sentiment from 2029 onward with rising averages, including 2030 avg $6.03 (ROI 50.3) and 2050 avg $20.15 (ROI 402.5). However, forecasts are not guarantees and carry uncertainty.
Yes. Forecasts show years with max values above $10: 2032 max $10.73, 2034 max $10.95, 2035 max $14.61, 2040 max $18.16, and 2050 max $42.39.
Current price is $4.01 and market cap is $517.86M.
2035: min $5.11, avg $8.35, max $14.61 with ROI 108.3 and sentiment BULLISH.
Cytek Biosciences, Inc. Community Discussion
0Share your Cytek Biosciences, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.